ArticleFrontiers in oncology2026
Nanoparticle albumin-bound paclitaxel -induced severe interstitial lung disease in a gastric cancer patient: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel formulation that combines paclitaxel with human serum albumin via nanotechnology. Without the need for solubilizers, it allows for higher safe doses, shorter infusion time, and no premedication for hypersensitivity prevention. nab-PTX has been widely used in the treatment of various solid tumors. Its common adverse reactions include fatigue, alopecia, myelosuppression, etc., while pulmonary toxicity is extremely rare. To date, there are no reports of severe drug-induced interstitial lung disease (DILD) caused by nab-PTX in gastric cancer patients. Case presentation: We report a case of a 77-year-old male patient with gastric adenocarcinoma. On the 15th day after receiving second-line nab-PTX monotherapy, the patient developed chest tightness, dyspnea, high fever, and severe respiratory distress. High-resolution computed tomography (HRCT) of the chest showed diffuse exudative changes in both lungs, involving more than 90% of the lung fields. After excluding other causes such as pulmonary infection and tumor progression, the patient was diagnosed with severe nab-PTX-related DILD. nab-PTX was discontinued immediately, and the patient was treated with intravenous methylprednisolone sodium succinate. Subsequently, the pulmonary inflammation was gradually absorbed, and the clinical symptoms were significantly improved. Conclusion: nab-PTX-induced severe interstitial pneumonia in gastric cancer patients is a rare and life-threatening adverse event. Clinicians should closely monitor respiratory symptoms and signs of patients receiving nab-PTX, achieve early identification and timely intervention, so as to reduce the risk of adverse outcomes and improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.